Metabolic Syndrome — Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Citation(s)
A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH